Needham analyst Ami Fadia has maintained their bullish stance on ALKS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia has given her Buy rating due to a combination of factors that highlight Alkermes’ strong financial performance and positive outlook. The company reported third-quarter earnings that significantly surpassed expectations, with an EPS of $0.49, which is 58% higher than the consensus estimate. This impressive result was largely driven by higher-than-anticipated revenues, with notable sales growth across all product lines, including Vivitrol, Aristada, and Lybalvi.
Moreover, management has raised its revenue guidance for 2025, indicating confidence in continued growth. The company also made adjustments to its R&D and COGS expense ranges, while increasing its SG&A expense guidance. These strategic financial moves, combined with the robust sales performance, suggest a positive trajectory for Alkermes, justifying the Buy rating.
Fadia covers the Healthcare sector, focusing on stocks such as Immuneering, Biogen, and Merus. According to TipRanks, Fadia has an average return of 16.3% and a 51.40% success rate on recommended stocks.
In another report released today, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $45.00 price target.